FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Toxin Application
Agency requests additional manufacturing information and does not cite safety or efficacy concerns or require new clinical studies.
Agency requests additional manufacturing information and does not cite safety or efficacy concerns or require new clinical studies.
